What's in Alkermes, Inc.'s pipeline?

Alkermes, Inc. has 29 drugs in our index: 6 marketed, 0 filed, 12 in Phase 3, 3 in Phase 2, 8 in Phase 1.

Which companies overlap with Alkermes, Inc.'s portfolio?

Top competitors by shared drug class: AbbVie, New York State Psychiatric Institute, Acacia Pharma Ltd, All India Institute of Medical Sciences, Bhubaneswar, Assistance Publique - Hôpitaux de Paris.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/alkermes-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Alkermes, Inc. — Portfolio Competitive Intelligence Brief

Alkermes, Inc. pipeline: 6 marketed, 0 filed, 12 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

6 marketed 0 filed 12 Phase 3 3 Phase 2 8 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Lybalvi	SAMIDORPHAN	marketed	Atypical Antipsychotic [EPC]	Mu-type opioid receptor	Neuroscience	2021-01-01
Aristada	ARIPIPRAZOLE LAUROXIL	marketed		D(2) dopamine receptor	Neuroscience	2015-01-01
LYBALVI	LYBALVI	marketed	Atypical antipsychotic with opioid antagonist	D2 dopamine receptor, 5-HT7 serotonin receptor, mu-opioid receptor	Psychiatry
VIVITROL 380mg	VIVITROL 380mg	marketed
Motrin	Motrin	marketed			Other
Baclofen ER	Baclofen ER	marketed	GABA-B receptor agonist	GABA-B receptor	Neurology
NTX/PBO-B	NTX/PBO-B	phase 3	Combination antiobesity agent (opioid antagonist + antidepressant)	Opioid receptors (naltrexone); norepinephrine and dopamine transporters (bupropion)	Obesity / Metabolic Disease
ALKS 9072	ALKS 9072	phase 3	Abuse-deterrent opioid analgesic	Mu opioid receptor (with opioid antagonist component)	Pain Management
High Dose ALKS 5461	High Dose ALKS 5461	phase 3	Opioid receptor partial agonist / antagonist combination	Mu-opioid receptor (partial agonist via buprenorphine; antagonist via samidorphan)	Pain Management / Psychiatry
Low Dose ALKS 5461	Low Dose ALKS 5461	phase 3	Opioid agonist-antagonist combination	Mu-opioid receptor (buprenorphine component); opioid receptor antagonism (samidorphan component)	Pain Management / Opioid Use Disorder
NTX/BUP	NTX/BUP	phase 3	Opioid agonist-antagonist combination	Mu-opioid receptor (μ-OR)	Psychiatry / Addiction Medicine
ALKS 3831	ALKS 3831	phase 3

Therapeutic area mix

Psychiatry/Neurology · 2
Neuroscience · 2
Pain Management · 2
Psychiatry · 2
Psychiatry / Addiction Medicine · 2
Neurology · 2
Pain Management / Opioid Use Disorder · 1
Obesity / Metabolic Disease · 1
Other · 1
Pain · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

2031-08-23 — Lybalvi · 11351166 · US
2031-08-23 — Lybalvi · 11241425 · US
2031-08-23 — Lybalvi · 9126977 · US
2031-08-23 — Lybalvi · 10300054 · US
2031-08-23 — Lybalvi · 10716785 · US
2031-08-23 — Lybalvi · 11185541 · US
2031-08-23 — Lybalvi · 9517235 · US
2031-08-30 — Lybalvi · 9119848 · US
2032-02-13 — Lybalvi · 8778960 · US

Competitive overlap (companies sharing drug classes)

AbbVie · 2 shared drug classes
New York State Psychiatric Institute · 2 shared drug classes
Acacia Pharma Ltd · 1 shared drug class
All India Institute of Medical Sciences, Bhubaneswar · 1 shared drug class
Assistance Publique - Hôpitaux de Paris · 1 shared drug class
AstraZeneca · 1 shared drug class
Benaroya Research Institute · 1 shared drug class
Alexza Pharmaceuticals, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Alkermes, Inc.:

Cite this brief

Drug Landscape (2026). Alkermes, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/alkermes-inc. Accessed 2026-05-14.